Comparative Pharmacology
Head-to-head clinical analysis: CLOMID versus MILOPHENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMID versus MILOPHENE.
CLOMID vs MILOPHENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (GnRH) and subsequent LH and FSH release, stimulating ovulation.
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
None Documented
None Documented
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator